Table 2.
Description of scores at baseline (mean ± standard deviation) and after 4 weeks of treatment by prazosin.
| Variable | Baseline(mean ± standard deviation) | After four weeks(mean ± standard deviation) | Percentage of improvement (%) | Significance compared to no improvement |
|---|---|---|---|---|
| UCLA-A | 2.89 ± 1.64 | 0.44 ± 0.62 | 84.6% | p < 0.001 |
| UCLA-B | 16.44 ± 3.60 | 2.61 ± 2.70 | 84.1% | p < 0.001 |
| UCLA-C | 4.89 ± 2.08 | 0.78 ± 0.94 | 84.1% | p < 0.001 |
| UCLA-D | 16.67 ± 5.41 | 7.39 ± 3.73 | 55.7% | p < 0.001 |
| UCLA-E | 18.67 ± 4.46 | 7.67 ± 4.39 | 58.9% | p < 0.001 |
| UCLA-Total | 56.44 ± 12.78 | 18.50 ± 9.65 | 67.2% | p < 0.001 |
| SLEEP score | 6.44 ± 1.62 | 1.33 ± 1.53 | 79.3% | p < 0.001 |
| CGI-S | 5.28 ± 0.90 | 2.94 ± 0.73 | 44.1% | p < 0.001 |
CGI-S, Clinical Global Impression-Severity; UCLA-A, cluster A of ULCA-PTSD-RI; UCLA-B, cluster B of ULCA-PTSD-RI; UCLA-C, cluster C of ULCA-PTSD-RI; UCLA-D, cluster D of ULCA-PTSD-RI; UCLA-E, cluster E of ULCA-PTSD-RI; UCLA-Total, total score of ULCA-PTSD-RI.